Brokers Issue Forecasts for PRQR Q1 Earnings

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for ProQR Therapeutics in a report issued on Monday, March 16th. HC Wainwright analyst A. Ghosh forecasts that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for ProQR Therapeutics’ FY2030 earnings at $0.18 EPS.

Other equities analysts have also recently issued reports about the stock. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Thursday, January 22nd. Wall Street Zen upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday. Finally, Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research report on Friday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, ProQR Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $6.80.

ProQR Therapeutics Trading Down 3.3%

NASDAQ PRQR opened at $1.76 on Tuesday. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $3.10. The company has a market cap of $185.43 million, a PE ratio of -3.83 and a beta of 0.21. The stock’s 50-day moving average price is $1.64 and its two-hundred day moving average price is $2.06.

ProQR Therapeutics (NASDAQ:PRQR) last released its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The business had revenue of $5.50 million during the quarter, compared to the consensus estimate of $6.12 million. ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Osaic Holdings Inc. raised its holdings in ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 4,500 shares in the last quarter. Guggenheim Capital LLC acquired a new stake in shares of ProQR Therapeutics in the fourth quarter worth about $35,000. Moody Lynn & Lieberson LLC bought a new stake in shares of ProQR Therapeutics during the 4th quarter worth about $50,000. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics during the 4th quarter worth about $51,000. Finally, Fifth Third Bancorp acquired a new position in shares of ProQR Therapeutics during the 3rd quarter valued at about $64,000. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.